Heart failure & cardiomyopathiesMeta-analysis
Empagliflozin in Heart Failure and Previous Coronary Revascularization
- prospectively designed pooled analysis of the EMPEROR-Reduced (NCT03057977) and EMPEROR-Preserved (NCT03057951) trials
- randomized
- EMPEROR-Pooled database
Authors' conclusion
In this large HF trial program, revascularized patients with HF exhibited similar rates of HF and ischemic events as those without prior revascularization. The efficacy and safety of empagliflozin in HF were consistent in those with and without a revascularization history.
Study context
- Population
- Patients with heart failure (HF) with a left ventricular ejection fraction below and above 40%, analysed by history of coronary revascularizationpooled EMPEROR-Reduced and EMPEROR-Preserved participants · REVASC 3,437 · no REVASC 6,281
- Participants
- 9,718 patients
- Comparison
- Empagliflozin or placebo, by history of coronary revascularization
- REVASCn = 3,437
- no REVASCn = 6,281
- Outcome
- Time to first HF hospitalization or cardiovascular death
Pooled result
As reported in the abstract
- REVASC
- 0.76 (CI 0.66–0.89)
- no REVASC
- 0.77 (CI 0.68–0.87)
Further pooled results
Clinical outcomes, including the primary outcome and 3-point major adverse cardiac and cerebrovascular event, by revascularization history (placebo group)
- A history of revascularization was not associated with an elevated risk of clinical outcomes
3-point major adverse cardiac and cerebrovascular event
- Empagliflozin had neutral effect in both groups
Follow-up
- Median follow-up time
- 21.23 months (IQR: 14.93-28.97 months)
Original publication
Empagliflozin in Heart Failure and Previous Coronary Revascularization. JACC Adv. doi:10.1016/j.jacadv.2025.102419
Summarised from the published abstract; every number is checked against it